Simcere Pharmaceutical Group Limited
2096
Rang in aandelen
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Aandeelprijs
$1.32
Marktkapitalisatie
$3.40B
Verandering (1 dag)
-4.51%
Verandering (1 jaar)
-19.88%
Land
CN
Handel Simcere Pharmaceutical Group Limited (2096)
Categorie
Healthcare
Omzet van Simcere Pharmaceutical Group Limited (2096)
Omzet in Oct 2026 TTM: 0
Volgens de laatste financiële rapporten van Simcere Pharmaceutical Group Limited bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Simcere Pharmaceutical Group Limited van 2012 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2025 | $1.11B | 21.56% |
| 2024 | $909.04M | -2.62% |
| 2023 | $933.49M | 1.90% |
| 2022 | $916.09M | 16.46% |
| 2021 | $786.63M | 13.97% |
| 2020 | $690.18M | -4.58% |
| 2019 | $723.31M | 10.22% |
| 2018 | $656.27M | 10.39% |
| 2017 | $594.50M | 77.98% |
| 2012 | $334.03M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
